Mélissa Chénard

1.6k total citations
13 papers, 605 citations indexed

About

Mélissa Chénard is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Mélissa Chénard has authored 13 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Organic Chemistry. Recurrent topics in Mélissa Chénard's work include Peptidase Inhibition and Analysis (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Protein Degradation and Inhibitors (4 papers). Mélissa Chénard is often cited by papers focused on Peptidase Inhibition and Analysis (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Protein Degradation and Inhibitors (4 papers). Mélissa Chénard collaborates with scholars based in United States and Canada. Mélissa Chénard's co-authors include Brian B. Haines, Astrid M. Kral, William T. Arthur, Brian S. Roberts, Theresa Zhang, Andrey Loboda, Igor Feldman, Judith C. Fleming, Yair Benita and Christopher Winter and has published in prestigious journals such as Biochemistry, Cancer Research and American Journal of Physiology-Cell Physiology.

In The Last Decade

Mélissa Chénard

13 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mélissa Chénard United States	10	453	194	150	69	56	13	605
Theonie Anastassiadis United States	5	602 1.3×	178 0.9×	181 1.2×	82 1.2×	58 1.0×	6	817
Qiaodan Zhou China	10	535 1.2×	105 0.5×	132 0.9×	72 1.0×	62 1.1×	21	815
Marc R. Arnone United States	7	474 1.0×	122 0.6×	201 1.3×	113 1.6×	55 1.0×	7	620
Carrow I. Wells United States	18	566 1.2×	109 0.6×	187 1.2×	132 1.9×	43 0.8×	46	843
Alexander Gozman United States	8	612 1.4×	139 0.7×	120 0.8×	61 0.9×	53 0.9×	22	778
Niru B. Soni United States	13	488 1.1×	203 1.0×	218 1.5×	189 2.7×	47 0.8×	17	788
Vivek Modi United States	9	494 1.1×	156 0.8×	98 0.7×	74 1.1×	24 0.4×	12	643
Göran Dahl Sweden	14	462 1.0×	87 0.4×	147 1.0×	78 1.1×	32 0.6×	22	677
Randy Hoffman United States	5	544 1.2×	114 0.6×	103 0.7×	102 1.5×	28 0.5×	6	678
Vasileios Stathias United States	10	388 0.9×	200 1.0×	85 0.6×	32 0.5×	93 1.7×	21	644

Countries citing papers authored by Mélissa Chénard

Since Specialization

Citations

This map shows the geographic impact of Mélissa Chénard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mélissa Chénard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mélissa Chénard more than expected).

Fields of papers citing papers by Mélissa Chénard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mélissa Chénard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mélissa Chénard. The network helps show where Mélissa Chénard may publish in the future.

Co-authorship network of co-authors of Mélissa Chénard

This figure shows the co-authorship network connecting the top 25 collaborators of Mélissa Chénard. A scholar is included among the top collaborators of Mélissa Chénard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mélissa Chénard. Mélissa Chénard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

O’Neil, Jennifer, Yair Benita, Igor Feldman, et al.. (2016). An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. Molecular Cancer Therapeutics. 15(6). 1155–1162. 227 indexed citations

Čemerski, Sašo, Shuxia Zhao, Mélissa Chénard, et al.. (2015). T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity. Journal for ImmunoTherapy of Cancer. 3(S2). 6 indexed citations

Kral, Astrid M., Nicole Ozerova, Joon Jung, et al.. (2014). Divergent Kinetics Differentiate the Mechanism of Action of Two HDAC Inhibitors. Biochemistry. 53(4). 725–734. 16 indexed citations

Loboda, Andrey, Michael Nebozhyn, Jason P. Frazier, et al.. (2010). A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics. 3(1). 26–26. 107 indexed citations

Blackman, Samuel C., Scot Ebbinghaus, Alessandra Di Bacco, et al.. (2010). Abstract 3478: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical models. Cancer Research. 70(8_Supplement). 3478–3478. 1 indexed citations

Heidebrecht, Richard W., Mélissa Chénard, William K. Dahlberg, et al.. (2009). Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters. 19(7). 2053–2058. 17 indexed citations

Haines, Brian B., Mélissa Chénard, Raquel Sevilla, et al.. (2009). A Quantitative Volumetric Micro-Computed Tomography Method to Analyze Lung Tumors in Genetically Engineered Mouse Models. Neoplasia. 11(1). 39–47. 36 indexed citations

Wilson, Kevin J., David J. Witter, Jonathan B. Grimm, et al.. (2008). Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1). Bioorganic & Medicinal Chemistry Letters. 18(6). 1859–1863. 20 indexed citations

Methot, Joey L., Christopher L. Hamblett, Joon Jung, et al.. (2008). SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters. 18(23). 6104–6109. 36 indexed citations

10.

Witter, David J., Paul E. Harrington, Kevin J. Wilson, et al.. (2007). Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters. 18(2). 726–731. 80 indexed citations

11.

Bouley, Richard, Tian‐Xiao Sun, Mélissa Chénard, et al.. (2003). Functional role of the NPxxY motif in internalization of the type 2 vasopressin receptor in LLC-PK1 cells. American Journal of Physiology-Cell Physiology. 285(4). C750–C762. 46 indexed citations

12.

Chénard, Mélissa, et al.. (2001). Gastric cancer cell lines as models to study human digestive functions. Journal of Cellular Biochemistry. 81(2). 241–251. 1 indexed citations

13.

Chénard, Mélissa, et al.. (2000). Expression of integrin subunits correlates with differentiation of epithelial cell lineages in developing human gastric mucosa. Anatomy and Embryology. 202(3). 223–233. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact